No business profile yet.
Size Clarity Pharmaceuticals (CU6.AX) is an Australia Health Care company (Medical Specialties) with a market value of $444M, the 270th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.83 on 18 Nov 2026.
Performance Over six months the shares fell 33.2%, against -15.8% for the median peer and +1.2% for the Australia market (cap-weighted) — 4th lowest of 21 in its peer set.
Valuation It trades at 3.56× book value against a peer median of 2.58× (5th most expensive of 21).
Price implies The share price implies a return on equity of about 44.2%; Clarity Pharmaceuticals delivers -77.5%, so the price asks more than the business earns today.
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$0 | A$0 | A$0 | A$0 | A$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -A$283,530 | -A$283,530 | -A$185,083 | -A$153,068 | -A$100,513 |
| EBITDA | -A$119M | -A$119M | -A$78.4M | -A$56.2M | -A$36.1M |
| Net income | -A$107M | -A$107M | -A$64.3M | -A$42.3M | -A$24.6M |
| Free cash flow | -A$92.9M | -A$92.9M | -A$55.0M | -A$43.7M | -A$27.5M |
| Capital expenditure | A$306,922 | A$306,922 | A$182,743 | A$504,005 | A$46,562 |
| Total debt | n/a | A$0 | A$0 | A$0 | A$0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CU6.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | -6.4% | 6th highest of 21 |
| 6-month return | -33.2% | -15.8% | 4th lowest of 21 |
| Return on equity | -77.5% | 1.2% | 2nd lowest of 21 |
| Price / book | 3.56× | 2.58× | 5th most expensive of 21 |
| ROE the price implies | 44.2% | 16.0% | 2nd most demanding of 21 |
| ROE delivered | -77.5% | 1.2% | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Clarity Pharmaceuticals CU6.AX | Australia | $444M | -33% | n/a | -78% | 3.56× | 44.2% | -77.5% |
| Huaren Pharmaceutical 300110.SZ | China | $440M | -16% | -3% | -44% | 3.39× | 16.6% | -44.2% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $436M | +39% | +5% | 2% | 2.33× | 22.1% | 2.0% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 8% | 1.04× | 9.2% | 7.9% |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 2% | 0.61× | 4.7% | 1.8% |
| Mobia Medical MOBI | United States | $434M | +2% | +105% | -246% | 2.75× | 12.8% | n/a |
| Shoulder Innovations SI | United States | $432M | +39% | +55% | -25% | 3.65× | 16.0% | -25.1% |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -68% | 26.75× | 70.0% | -68.1% |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | -1% | 1.87× | 13.9% | -0.5% |
| Revenio REG1V.HE | Finland | $428M | -34% | +44% | 9% | 1.74× | 11.5% | 9.1% |
| China Isotope & Radiation 1763.HK | Hong Kong | $428M | -41% | -5% | 6% | 0.58× | 5.9% | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $425M | -16% | +10% | 24% | 2.80× | 18.2% | 23.7% |
| MiMedx MDXG | United States | $464M | -16% | -23% | -9% | 2.20× | 20.4% | -8.5% |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 4% | 1.68× | 10.5% | 4.2% |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 1% | 2.61× | 18.3% | 0.7% |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 2% | 1.73× | 9.3% | 1.8% |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -18% | 2.56× | 16.0% | -18.3% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -19% | 2.93× | 13.4% | -19.2% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 15% | 5.20× | 21.5% | 15.5% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -10% | 2.91× | 18.4% | -10.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 16% | 3.71× | 18.3% | 15.8% |